Skip to main content
ADMA logo

ADMA · Adma Biologics, Inc. · Executive Compensation

Track ADMA — free
Market Cap
$2.96B
Shares
221.85M
Volume · Nov 20 284.76K Avg daily vol (3M) 3.2M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Adam Grossman $10,237,326
Kaitlin Kestenberg $3,488,647
Brad L. Tade $2,823,630
Paul Terence Kohler $2,296,949
Fiscal 2024
Executive Total
Adam Grossman $7,918,734
Kaitlin Kestenberg $3,340,020
Brad L. Tade $2,936,435
Paul Terence Kohler —
Fiscal 2023
Executive Total
Adam Grossman $6,039,649
Brian Lenz $1,965,360
Brad L. Tade —
Paul Terence Kohler —
Kaitlin Kestenberg —
Fiscal 2022
Executive Total
Adam Grossman $2,649,501
Brian Lenz $1,601,064
Kaitlin Kestenberg —
Brad L. Tade —
Fiscal 2021
Executive Total
Adam Grossman $4,361,250
Brian Lenz $2,366,680
Fiscal 2020
Executive Total
Adam Grossman $1,962,141
Dr. James Mond $1,195,348
Brian Lenz $1,087,018
Fiscal 2019
Executive Total
Adam Grossman $1,702,022
Dr. James Mond $1,237,422
Brian Lenz $1,122,154
Fiscal 2018
Executive Total
Adam Grossman $1,553,300
Dr. James Mond $1,045,449
Brian Lenz $940,094

Executive changes

Person Change Filed
Terry Kohler Appointed 2026-02-25
Brad Tade Retired 2026-02-25
Terry Kohler Appointed 2026-02-25
Brad Tade Retired 2026-02-25
Eduardo Rene Salas Appointed 2025-01-02
Alison C. Finger Appointed 2024-11-21
Young T. Kwon, PhD Appointed 2024-11-21
Steven A. Elms Appointed 2024-11-21
Bryant E. Fong
“There are no disagreements between Mr. Fong and the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2024-11-21
Brad Tade Appointed 2024-07-26
Kaitlin Kestenberg Appointed 2024-04-02
Adam Grossman Appointed 2024-02-28
Alison C. Finger Appointed 2023-10-02
Lawrence P. Guiheen Appointed 2022-06-21
Jerrold B. Grossman D.P.S. Appointed 2022-06-21
Young T. Kwon, Ph.D. Appointed 2021-10-18
James Mond Resigned 2021-06-14

Leadership

Key facts CIK 1368514 CUSIP 000899104 13F (30d) 333 filings 305 filers Visit website Investor relations